Loading...
XJPX4588
Market cap81mUSD
Jan 21, Last price  
508.00JPY
1D
-0.59%
1Q
-21.85%
Jan 2017
-52.92%
IPO
-84.42%
Name

Oncolys Biopharma Inc

Chart & Performance

D1W1MN
XJPX:4588 chart
P/E
—
P/S
200.39
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.56%
Rev. gr., 5y
-17.86%
Revenues
63m
-93.54%
396,754,0001,180,00028,797,000121,303,000178,313,000229,139,000168,549,0001,303,844,000314,179,000642,494,000976,182,00063,038,000
Net income
-1.94b
L+68.72%
-102,829,000-635,553,000-738,999,000-857,290,000-931,397,000-1,090,703,000-1,233,846,000-912,345,000-2,095,086,000-1,615,439,000-1,148,937,000-1,938,505,000
CFO
-1.34b
L-22.14%
-151,349,000-598,528,000-814,489,000-755,756,000-903,424,000-1,096,840,000-1,187,579,000-238,228,000-1,465,199,000-1,741,827,000-1,717,135,000-1,336,922,000

Profile

Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
URL
https://www.oncolys.com/
IPO date
Dec 06, 2013
Employees
40
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
63,038
-93.54%
976,182
51.94%
Cost of revenue
1,384,373
1,585,186
Unusual Expense (Income)
NOPBT
(1,321,335)
(609,004)
NOPBT Margin
Operating Taxes
2,926
2,932
Tax Rate
NOPAT
(1,324,261)
(611,936)
Net income
(1,938,505)
68.72%
(1,148,937)
-28.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,223,450
(28)
BB yield
-12.12%
0.00%
Debt
Debt current
135,341
231,357
Long-term debt
206,123
172,641
Deferred revenue
Other long-term liabilities
8,141
7,749
Net debt
(1,212,416)
(1,328,318)
Cash flow
Cash from operating activities
(1,336,922)
(1,717,135)
CAPEX
(5,686)
(1,358)
Cash from investing activities
(5,392)
20,117
Cash from financing activities
1,142,542
(113,830)
FCF
(694,613)
(864,420)
Balance
Cash
1,532,844
1,711,280
Long term investments
21,036
21,036
Excess cash
1,550,728
1,683,507
Stockholders' equity
249,966
1,572,986
Invested Capital
1,547,442
984,760
ROIC
ROCE
EV
Common stock shares outstanding
17,797
17,327
Price
567.00
7.59%
527.00
-0.19%
Market cap
10,091,103
10.51%
9,131,543
2.24%
EV
8,878,687
7,803,225
EBITDA
(1,319,049)
(608,090)
EV/EBITDA
Interest
3,602
3,945
Interest/NOPBT